Pregled bibliografske jedinice broj: 434001
The Impact of Timing of Humalog Mix25 Injections on Blood Glucose Fluctuations in the Postprandial Period in Elderly Patients with Type 2 Diabetes
The Impact of Timing of Humalog Mix25 Injections on Blood Glucose Fluctuations in the Postprandial Period in Elderly Patients with Type 2 Diabetes // Medical Science Monitor, 11 (2005), 12; 87-92 (međunarodna recenzija, članak, znanstveni)
CROSBI ID: 434001 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
The Impact of Timing of Humalog Mix25 Injections on Blood Glucose Fluctuations in the Postprandial Period in Elderly Patients with Type 2 Diabetes
Autori
Galić, Edvard ; Vrtovec, Matjaž ; Božikov, Velimir ; Schwarzenhofer, Maria ; Miličević, Zvonko
Izvornik
Medical Science Monitor (1234-1010) 11
(2005), 12;
87-92
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
postmeal insulin lispro; insulin pens; elderly patients with diabetes; oral agent failure; Humalog Mixture 25; glibenclamide; type 2 diabetes; postprandial blood glucose; glycosylated hemoglobin A1c
Sažetak
Background: Postprandial hyperglycemia contributes to glycation of hemoglobin A1c and has been associated with cardiovascular risk in people with diabetes. We investigated the impact of injection timing of Humalog® Mix25™ ; (Mix25, known as Humalog® Mix75/25 in the U.S.: 25% insulin lispro and 75% neutral protamine lispro) on glycemia and postprandial blood glucose (BG) excursions in elderly individuals. Material/Methods: Seventy-three patients aged 60 to 80 years were randomized to Mix25 (Mix25 group, 37 participants) or a continuation with maximum dose glibenclamide (control group, 36 participants). The Mix25 group was subdivided into a group of 18 patients who were injecting insulin after meals and 19 who were injecting before. Results: At baseline, the absolute postprandial BG concentrations and postprandial BG excursions after breakfast were high (Mix25 group: 15.3±4.8 mmol/l and 3.5±2.7 mmol/l, respectively ; controls: 15.4±3.9 mmol/l and 4.7±2.7 mmol/l, respectively). In both groups improvement was observed at the endpoint, but it was greater with Mix25 (Mix25 group: 10.3±3.6 mmol/l, p<0.0001 vs. baseline, p<0.003 vs. controls, and 2.0±2.5 mmol/l, p<0.008 vs. baseline, p=ns vs. controls ; control group: 13.3±2.9 mmol/l, p<0.006 vs. baseline, and 4.7±2.7 mmol/l, p<0.006 vs. baseline). The two Mix25 subgroups had similar postprandial BG levels and BG excursions after breakfast. Conclusions: Mix25 improves postprandial BG and yields a greater effect on BG excursions compared with monotherapy with glibenclamide. The timing of Mix25 did not impact the level of BG or BG fluctuations after meals, which may be important for individuals with changing dietary pattern.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
POVEZANOST RADA
Ustanove:
Medicinski fakultet, Osijek
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE